Gain Therapeutics Inc. (GANX)

AI Score

Unlock

AI Score

Our AI model analyzes fundamental, technical, and statistical indicators to predict the probability of a bullish trend over the next three months.

We regularly update and refine our models to deliver the most reliable forecasts for you.

Bullish Probability	Sentiment	Score
+80%	Strong Buy	10
+75%	Buy	9
+70%	Buy	8
+60%	Buy	7
+50%	Hold	6
+45%	Hold	5
+40%	Hold	4
+35%	Sell	3
+30%	Sell	2
+20%	Strong Sell	1

undefined

undefined%

At close: undefined

1.50

-7.98%

Pre-market Dec 16, 2024, 04:03 AM EST

Company Description

Gain Therapeutics, Inc., a biotechnology company, engages in developing various therapies to treat diseases caused by protein misfolding.

It focuses on rare genetic diseases and neurological disorders.

The company uses its Site-Directed Enzyme Enhancement Therapy platform to discover allosteric sites on misfolded proteins and identify proprietary small molecules that bind these sites, restore protein folding, and treat disease.

It is developing structurally targeted allosteric regulator candidates to treat various diseases, including Morquio B, GM1 gangliosidosis (GM1), neuronopathic Gaucher disease, GBA1 Parkinson's, Krabbe, and Mucopolysaccharidosis type 1 diseases.

The company was founded in 2017 and is based in Bethesda, Maryland.

Gain Therapeutics Inc.

Country	United States
IPO Date	Mar 19, 2021
Industry	Biotechnology
Sector	Healthcare
Employees	29
CEO	Gene Mack M.B.A.

Contact Details

Address: 4800 Montgomery Lane Bethesda, Maryland United States
Website	https://www.gaintherapeutics.com

Stock Details

Ticker Symbol	GANX
Exchange	NASDAQ
Fiscal Year	January - December
Reporting Currency	USD
CIK Code	0001819411
CUSIP Number	36269B105
ISIN Number	US36269B1052
Employer ID	85-1726310
SIC Code	2834

Key Executives

Name	Position
Gene Mack M.B.A.	Chief Financial Officer & Interim Chief Executive Officer
Dr. Joanne Taylor Ph.D.	Senior Vice President of Research
Dr. Jonas Hannestad M.D., Ph.D.	Chief Medical Officer
Dr. Khalid Islam Ph.D.	Executive Chairman
Dr. Terenzio Ignoni Pharm.D.	Senior Vice President of Technical Operations

Latest SEC Filings

Date	Type	Title
Nov 14, 2024	10-Q	Quarterly Report
Nov 14, 2024	8-K	Current Report
Oct 21, 2024	8-K	Current Report
Oct 08, 2024	8-K	Current Report
Sep 19, 2024	S-8	Filing
Sep 06, 2024	424B5	Filing
Sep 06, 2024	8-K	Current Report
Aug 12, 2024	4	Filing
Aug 12, 2024	4	Filing
Aug 08, 2024	10-Q	Quarterly Report

View All SEC Filings